.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Scientists at the National Institute of Nutrition (NIN) recently developed a poly-herbal blend for diabetes and obesity management. This innovative formulation combines five common kitchen ingredients: ginger, cinnamon, black pepper, amla, and turmeric. Beyond simple glucose control, the extract targets inflammation and oxidative stress. Consequently, it addresses the root causes of long-term diabetic complications that affect the heart and kidneys.
Researchers selected these five herbs after screening nearly 200 functional foods. They specifically focused on inhibiting advanced glycation end products (AGEs). These compounds contribute significantly to chronic damage in patients with diabetes. The team tested each ingredient individually before establishing a precise, scientifically backed composition. Furthermore, preclinical studies showed promising results in reducing both blood glucose and body weight. Because it is not a random mixture, the formulation ensures consistent potency.
The National Institute of Nutrition clarifies that this extract serves as an add-on therapy. It is not a replacement for standard medical treatments like metformin or insulin. Instead, it offers a protective effect for the eyes, nerves, and vascular system. Currently, the formulation is standardized at the laboratory level. Human clinical trials are scheduled to begin shortly and will likely last up to a year. This development highlights a significant move toward integrative health solutions in India. Doctors may soon have a scientifically validated herbal tool to complement existing diabetic care plans.
Q1: What specific ingredients comprise this new formulation?
The extract consists of a precise, evidence-based blend of ginger, cinnamon, black pepper, amla, and turmeric.
Q2: Can this herbal blend replace existing diabetes medication?
No, researchers emphasize that the blend is intended as an add-on therapy to existing clinical treatments, not a substitute.
Q3: How long will the clinical trials for this extract take?
The clinical trials are expected to run for 9 to 12 months, with a full evaluation completed within 18 months.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
NIN scientists develop a poly-herbal extract using five common herbs to manage diabetes, obesity, and long-term complications through scientific integration...
5 months ago
A New York City initiative successfully distributed over 48,000 COVID-19 oral antiviral prescriptions through rapid home delivery in 2022. With 92% delivered within 24 hours, the program safeguarded vulnerable and elderly populations, establishing an equitable framework for emergency drug distribution.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
